As a part of a 2018 NETRF Pilot Award, Justin Annes, MD, PhD, Stanford University, studied the levels of an enzyme called PAM (short for Peptidylglycine α-amidating monooxygenase) in primary NET tissue specimens donated by 109 patients between 1992-2013. The retrospective analysis of these specimens showed that a novel test for an enzyme secreted by neuroendocrine cells may help predict the course and outcome of neuroendocrine cancers.
- Pheo Para Awareness Week – August 23-29
- HOOFING IT Across Canada for Neuroendocrine Cancer Research!
- AMEND Launches New PPGL GenNET Group
- Global Disparities in Quality Healthcare for NETs at ASCO Quality Care Symposium
- INCA Research Chair and NeuroEndocrine Cancer Australia CEO Co-Authors Consensus Guidelines on LUNG NETs